Ocugen Inc. to Participate in a Cantor Fitzgerald Fireside Chat to Discuss COVAXIN COVID-19 Vaccine Development
Ocugen (NASDAQ: OCGN) announced its participation in a virtual Fireside Chat on March 31, 2021, with Cantor Fitzgerald. CEO Dr. Shankar Musunuri will discuss COVAXIN, a COVID-19 vaccine developed in collaboration with Bharat Biotech, highlighting safety and efficacy data, differences from mRNA vaccines, and pandemic conditions. The presentation aims to identify opportunities for COVAXIN in the U.S., where Ocugen expects to earn 45% of profits from sales.
- COVAXIN demonstrates 81% efficacy from Phase 1, 2, and interim Phase 3 data.
- Potential for COVAXIN to provide coverage against multiple protein antigens of the virus.
- Ocugen will receive 45% of profits from COVAXIN sales in the U.S.
- None.
MALVERN, Pa., March 29, 2021 (GLOBE NEWSWIRE) -- Ocugen, Inc. (NASDAQ: OCGN), a biopharmaceutical company focused on discovering, developing, and commercializing gene therapies to cure blindness diseases and developing a vaccine to save lives from COVID-19, today announced that it will present at a virtual Fireside Chat hosted by Cantor Fitzgerald and Kristen Kluska, Biotechnology Analyst, on March 31, 2021 from 10:00 a.m. - 11:00 a.m. ET.
Dr. Shankar Musunuri, Chairman, CEO, and Co-Founder of Ocugen will participate along with members of the Ocugen Vaccine Scientific Advisory Board to discuss COVAXIN COVID-19 vaccine development. Topics will include:
- Discussion on all COVAXIN safety and efficacy data generated to date from Bharat Biotech (private), including Phase 1, Phase 2, and interim Phase 3 data which demonstrated
81% efficacy. - Differentiation of COVAXIN (whole-virion inactivated vaccine) vs. other COVID-19 mRNA and adeno-based vaccines, including potential for coverage against multiple protein antigens of the virus.
- Thoughts on the current pandemic situation including new variants emerging.
- Highlight where the company views the greatest opportunity for COVAXIN in the United States, where they will receive
45% of the profits from any product sales.
Ocugen’s Vaccine Scientific Advisory Board members participating include: Satish Chandran, PhD – Wyeth Vaccines, Pfizer, Nucleonics, Somahlution; David Fajgenbaum, MD, MBA, MSc, FCPP – Translational Medicine & Human Genetics, University of Pennsylvania, Founding Director of Center for Cytokine Storm Treatment & Laboratory; and Bruce Forrest, MB, BS, MD, MBA – Wyeth Vaccines, Pfizer.
Presentation Details:
Format: Virtual Fireside Chat
Date: March 31, 2021
Time: 10:00 a.m. ET- 11:00 a.m. ET
Registration Link: https://us02web.zoom.us/webinar/register/WN_DKZBH0wuRo-5udQpml48qg
About Ocugen, Inc.
Ocugen, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing gene therapies to cure blindness diseases and developing a vaccine to save lives from COVID-19. Our breakthrough modifier gene therapy platform has the potential to treat multiple retinal diseases with one drug – “one to many” and our novel biologic product candidate aims to offer better therapy to patients with underserved diseases such as wet age-related macular degeneration, diabetic macular edema, and diabetic retinopathy. We are co-developing Bharat Biotech’s COVAXIN™ vaccine candidate for COVID-19 in the U.S. market. For more information, please visit www.ocugen.com.
Cautionary Note on Forward-Looking Statements
This press release contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995, which are subject to risks and uncertainties. We may, in some cases, use terms such as “predicts,” “believes,” “potential,” “proposed,” “continue,” “estimates,” “anticipates,” “expects,” “plans,” “intends,” “may,” “could,” “might,” “will,” “should” or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. Such forward-looking statements include information about qualitative assessments of available data, potential benefits, expectations for clinical trials, and anticipated timing of clinical trial readouts and regulatory submissions. This information involves risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. Risks and uncertainties include, among other things, the uncertainties inherent in research and development, including the ability to meet anticipated clinical endpoints, commencement and/or completion dates for clinical trials, regulatory submission dates, regulatory approval dates and/or launch dates, as well as risks associated with preliminary and interim data (including the Phase 3 interim data that is referenced in this release), including the possibility of unfavorable new clinical trial data and further analyses of existing clinical trial data; the risk that clinical trial data are subject to differing interpretations and assessments, including during the peer review/publication process, in the scientific community generally, and by regulatory authorities; whether and when data from Bharat Biotech’s clinical trials will be published in scientific journal publications and, if so, when and with what modifications; whether the U.S. Food and Drug Administration (FDA) will be satisfied with the design of and results from preclinical and clinical studies of COVAXIN, which have been conducted by Bharat Biotech in India; whether and when any biologics license and/or emergency use authorization applications may be filed in the United States for COVAXIN; whether and when any such applications may be approved by the FDA; decisions by the FDA impacting labeling, manufacturing processes, safety and/or other matters that could affect the availability or commercial potential of COVAXIN in the United States, including development of products or therapies by other companies. These and other risks and uncertainties are more fully described in our periodic filings with the Securities and Exchange Commission (SEC), including the risk factors described in the section entitled “Risk Factors” in the quarterly and annual reports that we file with the SEC. Any forward-looking statements that we make in this press release speak only as of the date of this press release. Except as required by law, we assume no obligation to update forward-looking statements contained in this press release whether as a result of new information, future events or otherwise, after the date of this press release.
Ocugen Contact:
Ocugen, Inc.
Sanjay Subramanian
Chief Financial Officer and Head of Corporate Development
IR@Ocugen.com
Media Contact:
LaVoieHealthScience
Lisa DeScenza
ldescenza@lavoiehealthscience.com
+1 9783955970
FAQ
What is the date and time of Ocugen's virtual Fireside Chat?
What topics will Ocugen discuss during the March 31 Fireside Chat?
What efficacy has been reported for COVAXIN?
How much profit will Ocugen retain from COVAXIN sales?
Who will join the CEO in the Fireside Chat?
